-
Sanofi's maintains its guidance for 2017 despite disappoiting Q3 results
BioSpace.com
November 03, 2017
The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in the third quarter, Chief Executive Officer Olivier Brandicourt announced Wednesday as the company revealed
-
Sanofi, Regeneron’s biologic shines again in asthma trial
pharmatimes
November 02, 2017
Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
-
Sanofi walks away from Voyager’s phase 2/3 Parkinson’s gene therapy
biospectrumasia
November 02, 2017
Under Voyager’s Collaboration Agreement with Sanofi Genzyme, Sanofi Genzyme had an exclusive option for ex-U.S. development and commercial rights to VY-AADC
-
Sanofi unveils new signature
expressbpd
October 20, 2017
Sanofi’s has unveiled its new Signature ‘Empowering Life’. ‘Empowering Life’ represents, in two powerful words, our ambition to support millions of people facing big and small health challenges, whether they be lifelong or temporary.
-
Sanofi plans summit to tackle diabetes in 5 million Nigerian citizens
pharmafile
October 18, 2017
Sanofi Aventis Nigeria plans to put together a National Diabetes Summit to address crisis in the country as five million of the nation’s citizens currently live with the condition.
-
New trial ordered, all previous judgements vacated in Sanofi, Amgen Praluent? (alirocumab) patent ca
pharmaasia
October 18, 2017
Sanofi and Regeneron will continue all regular Praluent? (alirocumab) sales and operations in the U.S. as usual in the meantime.
-
Aimmune Therapeutics to collaborate with Sanofi/Regeneron
biospectrumasia
October 18, 2017
The three companies are planning a 2018 midstage test of AR101 with adjunctive dupilumab in peanut-allergic patients
-
Sanofi India celebrates ‘DaanUtsav’
expressbpd
October 17, 2017
The company’s CSR team organised a series of activities where every employee was asked to spend four hours with children from vulnerable sections of society
-
Sanofi Invests €170M in New Vaccine Facility in France
contractpharma
October 16, 2017
Will allow Sanofi Pasteur to expand the global supply of its new quadrivalent influenza vaccine VaxigripTetra
-
EC grants marketing authorisation for Sanofi and Regeneron’s Dupixent for AD
pharmaceufical-technology
September 30, 2017
Approved for AD patients who are candidates for systemic therapy, Dupixent is the first targeted biologic in the European Union to receive authorisation for the chronic inflammatory disease.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
